- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Biocon employee penalized by SEBI for violating insider trading norms
Biocon Ltd's employee Girija Kelath violated the Prohibition of Insider Trading (PIT) Regulations by trading in the shares of Biocon during the trading window closure period, which is specifically prohibited.
New Delhi: Markets regulator Sebi on Thursday levied a fine of Rs 5 lakh on an employee of Biocon Ltd for violating insider trading norms while dealing in the scrip of the firm.
Biocon's employee Girija Kelath violated the Prohibition of Insider Trading (PIT) Regulations by trading in the shares of Biocon during the trading window closure period, which is specifically prohibited.
The order follows an investigation carried out by Sebi to ascertain if there was any violation of PIT norms by Girija Kelath, a designated person of Biocon, with respect to her transactions during August 31, 2018, to October 1, 2018.
The company had closed the trading window from October 1, 2018, till October 27, 2018. The compliance officer of Biocon had also intimated the designated employees, including Kelath, on September 28, 2018, about the start date and end date of trading window closure as well as the date of opening of the trading window.
"It is noted that the notice, being a designated person, had traded during the trading window closure period which is specifically prohibited. The notice is found to have sold 15,000 shares worth Rs. 1,00,50,000/- on the market on October 01, 2018," Sebi noted.
Notices refer to Girija Kelath.
Even when the trading window is open, a designated person is supposed to obtain pre-clearance of the trade from the compliance officer if the designated person's trade, cumulatively, whether in one transaction or a series of transactions, in any financial year, exceeds Rs 10 lakh (market value).
In a separate order, Sebi imposed a fine of Rs 2 lakh on for making delayed disclosure with respect to change in its shareholding in Sun and Shine Worldwide Ltd.
Shareholding of Saral Mining, formerly known as XO Infotech Ltd, in Sun and Shine Worldwide changed by more than 2 per cent on two occasions in May 2014. It also failed to make requisite disclosures to the company and the exchanges within the prescribed time frame, thereby violating market norms.
Through another order, the markets regulator penalized Samarth International Finlease Ltd with a fine of Rs 2 lakh for failing to redress investor grievances pending against it. It also did not submit action taken report with respect to the pending grievances within the prescribed period of time, as mandated by Sebi''s circulars.
Read also: Biocon names Anupam Jindal as new Chief Financial Officer
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751